Orthomyxoviridae (e.g., Influenza Virus, Fowl Plague Virus, Etc.) Patents (Class 424/209.1)
-
Publication number: 20090263423Abstract: This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.Type: ApplicationFiled: March 25, 2009Publication date: October 22, 2009Applicant: Juvaris BioTherapeutics, Inc.Inventors: Jeffery Fairman, Marla Lay Vaughn
-
Publication number: 20090263421Abstract: The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid molecule encoding an antigenic component thereof, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic. The invention further provides an adjuvant composition for use in a method of vaccination, the composition comprising or consisting of a population of T cells, wherein the T cells are (a) activated, or capable of being activated, and (b) apoptotic, or capable or being made apoptotic.Type: ApplicationFiled: May 10, 2006Publication date: October 22, 2009Inventors: Anna-Lena Spetz-Holmgren, Ulrika Johansson, Jan Anderson, Lilian Walther-jallow
-
Patent number: 7601490Abstract: The present invention includes compositions, methods and systems to isolate and characterize novel antiviral agents by contacting the antiviral agent with the F2F3 zinc fingers of a CPSF30 protein and an Influenza A NS1A protein; and determining whether the binding between the CPSF30 protein and the Influenza A NS1A protein is reduced.Type: GrantFiled: December 2, 2006Date of Patent: October 13, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Robert M. Krug, Karen Y. Twu
-
Patent number: 7601356Abstract: In certain aspects, the present invention provides methods for increasing the replication capacity of influenza viruses in hens' eggs and/or cell culture, recombinant and/or reassortant influenza viruses with increased replication capacity, and immunogenic and vaccine compositions comprising such recombinant and/or reassortant influenza viruses. In other aspects, the invention further provides nucleic acids encoding influenza genes associated with increased replication capacity, expression vectors comprising the nucleic acids of the invention, methods for making influenza viruses with increased replication capacity, and kits useful for practice of the methods.Type: GrantFiled: July 20, 2007Date of Patent: October 13, 2009Assignee: MedImmune, LLCInventors: Hong Jin, Bin Liu
-
Publication number: 20090246225Abstract: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.Type: ApplicationFiled: December 8, 2008Publication date: October 1, 2009Applicant: MedImmune, LLCInventors: George Robert Trager, George Kemble, Richard M. Schwartz, Harshvardhan Mehta, Vu Truong-Le, Zhongying Chen, Alfred A. Pan, Eric Tsao, Chiaoyin Kathy Wang, Luisa Yee, Palani Balu
-
Publication number: 20090232843Abstract: The instant invention provides methods for determining, predicting and characterizing the genetic variability of viruses, in particular, influenza. Accordingly, the invention provides methods for identifying virulent pathogens, genetic mutations within pathogens that are relevant to animal health, and methods and compositions for prophylactic or therapeutic intervention against such pathogens.Type: ApplicationFiled: January 4, 2008Publication date: September 17, 2009Inventor: Henry L. Niman
-
Publication number: 20090232844Abstract: The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).Type: ApplicationFiled: March 23, 2007Publication date: September 17, 2009Inventors: James Sutton, Nicholas Valiante
-
Patent number: 7588768Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: November 14, 2003Date of Patent: September 15, 2009Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
-
Patent number: 7588769Abstract: A method to prepare viruses with a mutant membrane protein gene, and viruses obtained by the method, are provided.Type: GrantFiled: April 20, 2004Date of Patent: September 15, 2009Assignee: Wisconsin Alumni Research FoundationInventor: Yoshihiro Kawaoka
-
Publication number: 20090220544Abstract: An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.Type: ApplicationFiled: November 6, 2006Publication date: September 3, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Rino Rappuoli, Derek O'Hagan, Giuseppe Del Giudice
-
Publication number: 20090220545Abstract: An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant.Type: ApplicationFiled: June 15, 2007Publication date: September 3, 2009Applicant: NOVARTIS AGInventors: Giuseppe Del Giudice, Riccardo Manetti
-
Publication number: 20090220543Abstract: The invention relates to a method of producing a HPV polypeptides and/or an influenza virus H5 polypeptide in a plant comprising the steps of cloning a HPV gene; and/or an influenza virus H5 gene or nucleic acid encoding their functional equivalents into a vector adapted to target components present in the plant, infiltrating at least a portion of the plant with the vector or transforming plant tissue with the vector so as to transiently express the HPV polypeptides and/or an influenza virus H5 polypeptide, and/or to create a transgenic plant; and recovering the HPV polypeptides and/or an influenza virus H5 polypeptide expressed by the plant. The invention further relates to vectors, transgenic plants or parts thereof and the progeny of such plants used in or which come about as a result of the method.Type: ApplicationFiled: May 2, 2006Publication date: September 3, 2009Inventors: Anna-Lise Williamson, Edward Peter Rybicki, James Malcolm MacLean, Inga Isabel Becker-Hitzeroth
-
Publication number: 20090220546Abstract: An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.Type: ApplicationFiled: February 20, 2009Publication date: September 3, 2009Inventors: Audino Podda, Nicola Groth, Michele Pellegrini
-
Publication number: 20090208523Abstract: Vaccine containing a first vaccine, adjuvated with an oil-in-water emulsion comprising 5% squalene, 0.5% polysorbate 80 and 0.5% sorbitan trioleate in aqueous citrate buffer pH 6.5, and a nonadjuvated second vaccine as combination partners for the simultaneous, separate or phased application for immunization against viral, bacterial or parasitic infectious diseases.Type: ApplicationFiled: April 22, 2009Publication date: August 20, 2009Inventor: Michael Broeker
-
Publication number: 20090208531Abstract: These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.Type: ApplicationFiled: February 16, 2007Publication date: August 20, 2009Applicant: National Institutes of Health Office of TechnologyInventors: Gary J. Nabel, Wing-pui Kong, Zhi-yong Yang
-
Publication number: 20090208532Abstract: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.Type: ApplicationFiled: February 12, 2009Publication date: August 20, 2009Applicant: Medlmmune, LLCInventors: Qi Dang, Richard Schwartz
-
Publication number: 20090202590Abstract: Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an aluminium salt.Type: ApplicationFiled: November 6, 2006Publication date: August 13, 2009Applicant: NOVARTIS VACCINES AND DIGNOSTICS SRLInventors: Anthony Colegate, Philip Sizer
-
Patent number: 7572620Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.Type: GrantFiled: January 11, 2005Date of Patent: August 11, 2009Assignee: Wisconsin Alumni Research FoundationInventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
-
Publication number: 20090196915Abstract: The invention provides compositions of influenza proteins, such as matrix and nucleoprotein, that are presented to an individual's immune system as multimeric displays to induce an immune response. The compositions are optionally associated with any type of immunomodulatory compound (IMC) comprising an immunostimulatory sequences (ISS). The invention further provides compositions of influenza matrix and nucleoproteins that can induce cellular and/or humoral immune response. The invention also provides methods of making and using these compositions, e.g., as a vaccine, for ameliorating symptoms associated with infection with influenza virus or for reducing the risk of infection with influenza virus.Type: ApplicationFiled: August 21, 2008Publication date: August 6, 2009Inventors: Gary VAN NEST, Brian D. LIVINGSTON, Georg ROTH, Deborah A. HIGGINS
-
Patent number: 7566454Abstract: Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein.Type: GrantFiled: February 24, 2006Date of Patent: July 28, 2009Assignee: University of MassachusettsInventors: Shan Lu, Shixia Wang
-
Patent number: 7566458Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: June 16, 2004Date of Patent: July 28, 2009Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20090186049Abstract: The present invention relates to methods for treating a range of cancers, for example MAGE positive cancers, including, but not limited to melanoma and non-small cell lung cancer (NSCLC). The present invention relates to methods for treating cancer in the adjuvant (eg. post-operative) setting and the active disease setting.Type: ApplicationFiled: May 24, 2007Publication date: July 23, 2009Inventors: Vincent Brichard, Frederic Eugene Lehmann
-
Publication number: 20090175902Abstract: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound.Type: ApplicationFiled: June 27, 2006Publication date: July 9, 2009Inventors: Haixiang Lin, Lie Tao Victor Li
-
Patent number: 7556940Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.Type: GrantFiled: March 28, 2005Date of Patent: July 7, 2009Assignee: Wyeth Holdings CorporationInventors: Jose M. Galarza, Theresa E. Latham
-
Publication number: 20090169505Abstract: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.Type: ApplicationFiled: November 12, 2008Publication date: July 2, 2009Inventors: Ruxandra Draghia-Akli, David B. Weiner, Jian Yan, Dominick Laddy
-
Publication number: 20090155330Abstract: A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer.Type: ApplicationFiled: October 10, 2008Publication date: June 18, 2009Applicant: Corium International, Inc.Inventors: Esi Ghartey-Tagoe, Janet Wendorf, Steve Williams, Parminder Singh, Robert Wade Worsham, Joseph C. Trautman, Danir Bayramov, Danny Lee Bowers, Andy Klemm, Steven Richard Klemm, Guohua Chen
-
Patent number: 7537768Abstract: The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo.Type: GrantFiled: February 9, 2007Date of Patent: May 26, 2009Assignee: Vical IncorporatedInventors: Catherine J. Luke, Adrian Vilalta, Mary K. Wloch, Thomas G. Evans, Andrew J. Geall, Gretchen S. Jimenez
-
Patent number: 7534596Abstract: A method of making a vaccine using animal derived component free (ADCF) cell culture technology, including the steps of attaching ADCF-adapted cells to a microcarrier including an attachment mechanism for attaching filipodia of the cells, the microcarrier being in a culture, growing the cells in ADCF maintenance media, infecting the cells with vaccine media, producing virus within the cells, and harvesting the virus. A vaccine produced by the above method in a pharmaceutically acceptable carrier. A vaccine production structure of ADCF-adapted cells removably attached to microcarrier beads including an attachment mechanism for attaching filipodia of the cells.Type: GrantFiled: February 12, 2007Date of Patent: May 19, 2009Assignee: Solohill Engineering, Inc.Inventors: Bonnie L. Wallace, William J. Hillegas
-
Publication number: 20090123495Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.Type: ApplicationFiled: August 8, 2006Publication date: May 14, 2009Applicant: Avir Green Hills Biotechnology Research Development Trade AGInventors: Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
-
Patent number: 7527800Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: May 20, 2005Date of Patent: May 5, 2009Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Patent number: 7528223Abstract: The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.Type: GrantFiled: July 24, 2003Date of Patent: May 5, 2009Assignee: Intercell AGInventors: Frank Mattner, Walter Schmidt, Andre Habel
-
Patent number: 7527798Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.Type: GrantFiled: January 14, 2004Date of Patent: May 5, 2009Assignee: The Wistar InstituteInventors: Walter Gerhard, Laslo Otvos
-
Publication number: 20090087448Abstract: The present invention generally relates to the field of immunology and provides immunoprotective compositions and methods for preparing such compositions from transgenic plant cells. The present invention also relates to the field of protein production (e.g., the recombinant production of enzymes, toxins, cell receptors, ligands, signal transducing agents, cytokines, or other proteins expressed in transgenic plant cell culture) and provides compositions comprising these proteins.Type: ApplicationFiled: October 2, 2008Publication date: April 2, 2009Applicant: DOW AGROSCIENCES LLCInventors: TIMOTHY JOE MILLER, Matthew James Fanton, Steven Robert Webb
-
Publication number: 20090087453Abstract: The present invention provides a virosome comprising a virosomal membrane comprising at least one lipid and envelope proteins of an enveloped virus and of the virosome and attached to said envelope proteins. Furthermore, the invention provides a vaccine comprising the virosome of the invention and, a method for the production of a virosome of the invention. Moreover, the invention provides a use of a virosome of the invention for the preparation of a vaccine, e.g. for the prevention or alleviation of a disease related to an HBV infection, and a method for the vaccination of a subject.Type: ApplicationFiled: October 20, 2005Publication date: April 2, 2009Inventors: Christian Moser, Giovanna Assero, Epifanio Fichera, Dario Ventura, Laurence Lempereur, Diana Felnerova
-
Patent number: 7510719Abstract: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.Type: GrantFiled: December 7, 2005Date of Patent: March 31, 2009Assignee: MedImmune, LLCInventors: Qi Dang, Richard Schwartz
-
Publication number: 20090081255Abstract: The invention relates to a method for producing flu virus according to which: a) immunizing a hen by administering a flu vaccine to the hen, b) triggering embryogenesis in one or more eggs of the immunized hen, c) infecting the one or more embryonated eggs by inoculating a flu virus into the allantoic cavity of the eggs, d) incubating the one or more infected embryonated eggs under temperature and humidity conditions that allow replication of the virus, and e) harvesting the allantoic fluid of the one or more incubated eggs containing the virus.Type: ApplicationFiled: September 26, 2008Publication date: March 26, 2009Applicant: SANOFI PASTEURInventors: Michel Marie Joseph Bublot, Francois-Xavier Le Gros, Catherine Gerdil, Catherine Moste, Isabelle Legastelois
-
Patent number: 7507411Abstract: Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.Type: GrantFiled: June 11, 2007Date of Patent: March 24, 2009Assignee: University of SaskatchewanInventors: Yan Zhou, Yeun-Kyung Shin, Lorne A. Babiuk, Qiang Liu
-
Patent number: 7507416Abstract: The recombinant live vaccine comprises a viral vector incorporating and expressing in vivo a heterologous nucleotide sequence, preferably a gene of a pathogenic agent, and at least one adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative. It is in particular a polymer of acrylic or methacrylic acid cross-linked with a polyalkenyl ether of a sugar or polyalcohol (carbomer), in particular cross-linked with an allyl sucrose or with allylpentaerythritol. It may also be a copolymer of maleic anhydride and ethylene cross-linked, for example, with divinyl ether.Type: GrantFiled: December 12, 2003Date of Patent: March 24, 2009Assignee: Merial LimitedInventors: Jean-Christophe Francis Audonnet, Jules Maarten Minke
-
Publication number: 20090074812Abstract: A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well the resulting virus and vaccines with the virus.Type: ApplicationFiled: June 18, 2008Publication date: March 19, 2009Applicant: Wisconsin Alumni Research FoundationInventors: Tokiko Watanabe, Yoshihiro Kawaoka
-
Publication number: 20090074815Abstract: A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine.Type: ApplicationFiled: April 21, 2006Publication date: March 19, 2009Applicant: SCICLONE PHARMACEUTICALS, INC.Inventors: Cynthia W. Tuthill, Alfred R. Rudolph
-
Publication number: 20090068224Abstract: The present invention provides novel methods to identify polypeptide ligands for Toll-like Receptors (TLRs), such as TLR2, TLR4 and TLR5. The method involves the use of phage display technology in an iterative biopanning procedure. The invention also provides polypeptide TLR ligands identified by the methods of the invention. In preferred embodiments, the polypeptide TLR ligands so identified modulate TLR signaling and thereby regulate the Innate Immune Response. The invention also provides vaccines comprising a polypeptide TLR ligand identified by the methods of the invention and an antigen. The invention also provides methods of modulating TLR signaling using the polypeptide TLR ligands and vaccines of the invention.Type: ApplicationFiled: January 26, 2006Publication date: March 12, 2009Applicant: VAXINNATE CORPORATIONInventors: Valerian Nakaar, Yan Huang, Thomas Powell
-
Publication number: 20090060950Abstract: The present invention provides a method for the manufacture of a preparation comprising virus antigens comprising a) inoculation of cells with infectious virus in a fluid, b) propagation of said virus in said cells, c) collecting said propagated virus, d) inactivating said collected virus, and e) treating said inactivated virus with a detergent, resulting in a preparation comprising viral antigens.Type: ApplicationFiled: August 28, 2008Publication date: March 5, 2009Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCAREInventors: Otfried Kistner, Christa Tauer, Noel Barrett, Wolfgang Mundt
-
Publication number: 20090060948Abstract: The present invention relates to a method to introduce a nucleic acid molecule into a fetid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune response. In one embodiment, this method enhances the immune response in a fetid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid to a felid. This method comprises parenterally administering to the fetid a composition that includes a nucleic acid molecule complexed with a cationic lipid.Type: ApplicationFiled: October 3, 2007Publication date: March 5, 2009Inventors: Joel R. Haynes, Ramani S. Wonderling, Dan T. Stinchcomb
-
Publication number: 20090060949Abstract: This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.Type: ApplicationFiled: January 23, 2008Publication date: March 5, 2009Inventors: David D. Ho, Yaoxing Huang, Ming Wei Chen, Rachel T.J. Cheng, Chi-Huey Wong, Alice Yu
-
Patent number: 7498424Abstract: The present invention relates to the identification of host cell proteins that interact with viral proteins required for virus replication, and high throughput assays to identify compounds that interfere with the specific interaction between the viral and host cell protein. Interfering compounds that inhibit viral replication can be used therapeutically to treat viral infection. The invention is based, in part, on the Applicants' discovery of novel interactions between proteins of the influenza virus and a human host cell proteins. One of these host cell proteins, referred to herein as NPI-1, interacts with influenza virus protein NP, and may be an accessory protein required for replication of influenza virus. Another of these host cell proteins, referred to herein as NS1I-1, interacts with influenza virus protein NS1. Compounds that interfere with the binding of the host cell and viral proteins, and inhibit viral replication can be useful for treating viral infection in vivo.Type: GrantFiled: November 24, 2003Date of Patent: March 3, 2009Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Peter Palese, Robert O'Neill
-
Publication number: 20090053264Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: April 22, 2008Publication date: February 26, 2009Inventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
-
Patent number: 7494656Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: November 20, 2006Date of Patent: February 24, 2009Assignee: Cytos Biotechnology AGInventors: Martin Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Patent number: 7494659Abstract: The invention relates to a simple and efficient process for isolating viruses from various sources and for producing live attenuated influenza vaccines in a serum-free Vero cell culture under conditions where alterations in the surface antigens of the virus due to adpative selection are minimized or prevented. The process does not require purification of the virus-containing supernatant harvested from the cell culture nor post-incubation treatment of the viruses for HA activation. The invention further relates to influenza A and B master strain candidates and to vaccines made thereof.Type: GrantFiled: September 25, 2001Date of Patent: February 24, 2009Assignee: Polymun Scientific Immunbiologische Forschung GmbHInventors: Hermann Katinger, Andre Egorov, Boris Ferko, Julia Romanova, Dietmar Katinger
-
Publication number: 20090041852Abstract: This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or non-reducing sugar and a biocompatible polymer, said dry powder composition being in the form of particles having an average particle size from 2 to 30 ?m and a particle size polydispersity from 1.1 to 4.0. This invention also relates to a method for producing said dry powder compositions and a system for vaccination of poultry by inhalation.Type: ApplicationFiled: March 15, 2007Publication date: February 12, 2009Applicant: UNIVERSITEIT GENTInventors: Jean Paul Remon, Chris Vervaet, Evy Corbanie
-
Publication number: 20090028814Abstract: A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer is disclosed. By adding a cationic polymer (in particular, a copolymer of aminoalkylmethacrylate or polyvinyl acetal diethylaminoacetate) or a cationic polymer plus a viscous polymer to a medicine of high molecular weight for producing a preparation in powder form, it is possible to achieve effective absorption of the medicine of high molecular weight through mucosa.Type: ApplicationFiled: September 13, 2007Publication date: January 29, 2009Inventors: Hideaki Nomura, Yosuke Ueki